Laboratory of Clinical Pathology and Medical Genetics, Foundation IRCCS Neurological Institute C. Besta, Via Celoria, 11, 20133, Milan, Italy.
J Neurooncol. 2013 Dec;115(3):353-63. doi: 10.1007/s11060-013-1236-x. Epub 2013 Sep 5.
Glioblastoma multiforme (GBM) is the most aggressive primary human brain tumor. The relatively high amount of T regulatory lymphocytes present in the tumor, contributes to the establishment of an immunosuppressive microenvironment. Samples of peripheral blood were collected from GBM patients and healthy controls and a purified population of Treg (CD4(+)/CD25(bright)) was isolated using flow cytometric cell sorting. Treg migrating capacities toward human glioma cell line conditioned medium were evaluated through an in vitro migration test. Our data show that supernatants collected from GBM cell lines were more attractant to Treg when compared to complete standard medium. The addition of an anti-CCL2 antibody to conditioned medium decreased conditioned medium-depending Treg migration, suggesting that CCL2 (also known as Monocyte Chemoattractant Protein, MCP-1) is implicated in the process. The number of circulating CD4(+)/μL or Treg/μL was similar in GBM patients and controls. Specific Treg markers (FOXP3; CD127; Helios; GITR; CTLA4; CD95; CCR2, CCR4; CCR7) were screened in peripheral blood and no differences could be detected between the two populations. These data confirm that the tumor microenvironment is attractive to Treg, which tend to migrate toward the tumor region changing the immunological response. Though we provide evidence that CCL2 is implicated in Treg migration, other factors are needed as well to provide such effect.
胶质母细胞瘤(GBM)是最具侵袭性的原发性人脑肿瘤。肿瘤中存在相对大量的调节性 T 淋巴细胞(Treg),有助于建立免疫抑制微环境。从 GBM 患者和健康对照者采集外周血样本,并使用流式细胞术分选分离出纯化的 Treg(CD4+/CD25bright)群体。通过体外迁移试验评估 Treg 向人神经胶质瘤细胞系条件培养基中的迁移能力。我们的数据表明,与完整标准培养基相比,从 GBM 细胞系收集的上清液对 Treg 更具吸引力。向条件培养基中添加抗 CCL2 抗体可降低条件培养基依赖的 Treg 迁移,表明 CCL2(也称为单核细胞趋化蛋白 1,MCP-1)参与了该过程。GBM 患者和对照组的循环 CD4+/μL 或 Treg/μL 数量相似。在外周血中筛选了特定的 Treg 标志物(FOXP3;CD127;Helios;GITR;CTLA4;CD95;CCR2、CCR4;CCR7),但在这两个群体之间未检测到差异。这些数据证实,肿瘤微环境对 Treg 具有吸引力,Treg 倾向于向肿瘤区域迁移,从而改变免疫反应。尽管我们提供了 CCL2 参与 Treg 迁移的证据,但还需要其他因素来提供这种作用。